Fibroblast heterogeneity in the cancer wound

Journal of Experimental Medicine

Volumn 211, Issue 8, 2014, Pages 1503-1523

  Öhlund, Daniel ^a   Elyada, Ela ^a   Tuveson, David ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CANCER ASSOCIATED FIBROBLAST; CANCER THERAPY; CARCINOGENESIS; CELL FUNCTION; CELL MIGRATION; CHRONIC INFLAMMATION; FIBROBLAST; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TISSUE REPAIR; TUMOR MICROENVIRONMENT;

CARCINOGENESIS; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84905103883     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20140692     Document Type: Review

References (263)

1. Ahrens, T., J.P. Sleeman, C.M. Schempp, N. Howells, M. Hofmann, H. Ponta, P. Herrlich, and J.C. Simon. 2001. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene. 20:3399-3408. http://dx.doi.org/10.1038/sj.onc.1204435.
2. Akhurst, R.J., and A. Hata. 2012. Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 11:790-811. http://dx.doi.org/10.1038/nrd3810.
3. Allinen, M., R. Beroukhim, L. Cai, C. Brennan, J. Lahti-Domenici, H. Huang, D. Porter, M. Hu, L. Chin, A. Richardson, et al. 2004. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 6:17-32. http://dx.doi.org/10.1016/j.ccr.2004.06.010.
4. Alvarez, R., M. Musteanu, E. Garcia-Garcia, P.P. Lopez-Casas, D. Megias, C. Guerra, M. Muñoz, Y. Quijano, A. Cubillo, J. Rodriguez-Pascual, et al. 2013. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer. 109:926-933. http://dx.doi.org/10.1038/bjc.2013.415.
5. Anderberg, C., and K. Pietras. 2009. On the origin of cancer-associated fibroblasts. Cell Cycle. 8:1461-1465. http://dx.doi.org/10.4161/cc.8.10.8557.
6. Aprelikova, O., X. Yu, J. Palla, B.-R. Wei, S. John, M. Yi, R. Stephens, R.M. Simpson, J.I. Risinger, A. Jazaeri, and J. Niederhuber. 2010. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle. 9:4387-4398. http://dx.doi.org/10.4161/cc.9.21.13674.
7. Aprelikova, O., J. Palla, B. Hibler, X. Yu, Y.E. Greer, M. Yi, R. Stephens, G.L. Maxwell, A. Jazaeri, J.I. Risinger, et al. 2013. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. 32:3246-3253. http://dx.doi.org/10.1038/onc.2012.351.
8. Armelin, H.A. 1973. Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc. Natl. Acad. Sci. USA. 70:2702-2706. http://dx.doi.org/10.1073/pnas.70.9.2702.
9. Augsten, M., C. Hägglöf, E. Olsson, C. Stolz, P. Tsagozis, T. Levchenko, M.J. Frederick, A. Borg, P. Micke, L. Egevad, and A. Ostman. 2009. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc. Natl. Acad. Sci. USA. 106:3414-3419. http://dx.doi.org/10.1073/pnas.0813144106.
10. Bachem, M.G., E. Schneider, H. Gross, H. Weidenbach, R.M. Schmid, A. Menke, M. Siech, H. Beger, A. Grünert, and G. Adler. 1998. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology. 115:421-432. http://dx.doi.org/10 .1016/S0016-5085(98)70209-4.
11. Bailey, J.M., A.M. Mohr, and M.A. Hollingsworth. 2009. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene. 28:3513-3525. http://dx.doi.org/10.1038/onc .2009.220.
12. Balsamo, M., F. Scordamaglia, G. Pietra, C. Manzini, C. Cantoni, M. Boitano, P. Queirolo, W. Vermi, F. Facchetti, A. Moretta, et al. 2009. Melanomaassociated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc. Natl. Acad. Sci. USA. 106:20847-20852. http://dx.doi.org/10.1073/pnas.0906481106.
13. Barcellos-Hoff, M.H., and S.A. Ravani. 2000. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60:1254-1260.
14. Barcellos-Hoff, M.H., C. Park, and E.G. Wright. 2005. Radiation and the microenvironment-tumorigenesis and therapy. Nat. Rev. Cancer. 5:867-875. http://dx.doi.org/10.1038/nrc1735.
15. Benvenuti, S., and P.M. Comoglio. 2007. The MET receptor tyrosine kinase in invasion and metastasis. J. Cell. Physiol. 213:316-325. http://dx .doi.org/10.1002/jcp.21183.
16. Berdiel-Acer, M., R. Sanz-Pamplona, A. Calon, D. Cuadras, A. Berenguer, X. Sanjuan, M.J. Paules, R. Salazar, V. Moreno, E. Batlle, et al. 2014. Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information. Mol. Oncol. http://dx.doi.org/10.1016/j.molonc.2014.04.006.
17. Bhowmick, N.A., A. Chytil, D. Plieth, A.E. Gorska, N. Dumont, S. Shappell, M.K. Washington, E.G. Neilson, and H.L. Moses. 2004. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 303:848-851. http://dx.doi.org/10.1126/science.1090922.
18. Bissell, M.J., and W.C. Hines. 2011. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17:320-329. http://dx.doi.org/10.1038/nm.2328.
19. Bizik, J., E. Kankuri, A. Ristimäki, A. Taïeb, H. Vapaatalo, W. Lubitz, and A. Vaheri. 2004. Cell-cell contacts trigger programmed necrosis and induce cyclooxygenase-2 expression. Cell Death Differ. 11:183-195. http://dx .doi.org/10.1038/sj.cdd.4401317.
20. Boire, A., L. Covic, A. Agarwal, S. Jacques, S. Sherifi, and A. Kuliopulos. 2005. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 120:303-313. http://dx.doi.org/10.1016/j.cell.2004.12.018.
21. Bollag, G., P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, H. Cho, W. Spevak, C. Zhang, Y. Zhang, G. Habets, et al. 2010. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 467:596-599. http://dx.doi.org/10.1038/nature09454.
22. Bourguignon, L.Y., P.A. Singleton, H. Zhu, and F. Diedrich. 2003. Hyaluronanmediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J. Biol. Chem. 278: 29420-29434. http://dx.doi.org/10.1074/jbc.M301885200.
23. Brennen, W.N., J.T. Isaacs, and S.R. Denmeade. 2012. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol. Cancer Ther. 11:257-266. http://dx.doi.org/10.1158/1535-7163.MCT-11-0340.
24. Brentnall, T.A., L.A. Lai, J. Coleman, M.P. Bronner, S. Pan, and R. Chen. 2012. Arousal of cancer-associated stroma: overexpression of palladin activates fibroblasts to promote tumor invasion. PLoS ONE. 7:e30219. http://dx.doi.org/10.1371/journal.pone.0030219.
25. Bronisz, A., J. Godlewski, J.A. Wallace, A.S. Merchant, M.O. Nowicki, H. Mathsyaraja, R. Srinivasan, A.J. Trimboli, C.K. Martin, F. Li, et al. 2012. Reprogramming of the tumour microenvironment by stromal PTENregulated miR-320. Nat. Cell Biol. 14:159-167. http://dx.doi.org/10 .1038/ncb2396.
26. Bronzert, D.A., P. Pantazis, H.N. Antoniades, A. Kasid, N. Davidson, R.B. Dickson, and M.E. Lippman. 1987. Synthesis and secretion of plateletderived growth factor by human breast cancer cell lines. Proc. Natl. Acad. Sci. USA. 84:5763-5767. http://dx.doi.org/10.1073/pnas.84.16.5763.
27. Calon, A., E. Espinet, S. Palomo-Ponce, D.V. Tauriello, M. Iglesias, M.V. Céspedes, M. Sevillano, C. Nadal, P. Jung, X.H. Zhang, et al. 2012. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell. 22:571-584. http://dx.doi.org/10.1016/j.ccr.2012.08.013.
28. Campbell, I., K. Polyak, and I. Haviv. 2009. Clonal mutations in the cancerassociated fibroblasts: the case against genetic coevolution. Cancer Res. 69:6765-6768. http://dx.doi.org/10.1158/0008-5472.CAN-08-4253.
29. Cardone, A., A. Tolino, R. Zarcone, G. Borruto Caracciolo, and E. Tartaglia. 1997. Prognostic value of desmoplastic reaction and lymphocytic infiltration in the management of breast cancer. Panminerva Med. 39:174-177.
30. Chaffer, C.L., and R.A. Weinberg. 2011. A perspective on cancer cell metastasis. Science. 331:1559-1564. http://dx.doi.org/10.1126/science.1203543.
31. Chang, C.C., W.H. Hsu, C.C. Wang, C.H. Chou, M.Y. Kuo, B.R. Lin, S.T. Chen, S.K. Tai, M.L. Kuo, and M.H. Yang. 2013. Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Res. 73:4147-4157. http://dx .doi.org/10.1158/0008-5472.CAN-12-4085.
32. Chapman, P.B., A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, et al. BRIM-3 Study Group. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507-2516. http://dx.doi.org/10.1056/NEJMoa1103782.
33. Charrier, A., and D.R. Brigstock. 2013. Regulation of pancreatic function by connective tissue growth factor (CTGF, CCN2). Cytokine Growth Factor Rev. 24:59-68. http://dx.doi.org/10.1016/j.cytogfr.2012.07.001.
34. Chaudhri, V.K., G.G. Salzler, S.A. Dick, M.S. Buckman, R. Sordella, E.D. Karoly, R. Mohney, B.M. Stiles, O. Elemento, N.K. Altorki, and T.E. McGraw. 2013. Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor. Mol. Cancer Res. 11:579-592. http://dx.doi.org/10.1158/1541-7786.MCR-12-0437-T.
35. Chauhan, V.P., J.D. Martin, H. Liu, D.A. Lacorre, S.R. Jain, S.V. Kozin, T. Stylianopoulos, A.S. Mousa, X. Han, P. Adstamongkonkul, et al. 2013. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4:2516. http://dx.doi.org/10.1038/ncomms3516.
36. Cheng, J., Y. Wang, A. Liang, L. Jia, and J. Du. 2012. FSP-1 silencing in bone marrow cells suppresses neointima formation in vein graft. Circ. Res. 110:230-240. http://dx.doi.org/10.1161/CIRCRESAHA.111.246025.
37. Cheng, J.D., M. Valianou, A.A. Canutescu, E.K. Jaffe, H.O. Lee, H. Wang, J.H. Lai, W.W. Bachovchin, and L.M. Weiner. 2005. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol. Cancer Ther. 4:351-360.
38. Cho, J.A., H. Park, E.H. Lim, and K.W. Lee. 2012. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int. J. Oncol. 40:130-138.
39. Choi, J., H. Kim, W.H. Jung, and J.S. Koo. 2013. Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res. 15:R78. http://dx.doi.org/10.1186/bcr3472.
40. Cirri, P., and P. Chiarugi. 2011. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 1:482-497.
41. Cordes, N., J. Seidler, R. Durzok, H. Geinitz, and C. Brakebusch. 2006. β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene. 25:1378-1390. http://dx.doi.org/10.1038/sj.onc.1209164.
42. Crawford, Y., I. Kasman, L. Yu, C. Zhong, X. Wu, Z. Modrusan, J. Kaminker, and N. Ferrara. 2009. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 15:21-34. http://dx.doi.org/10 .1016/j.ccr.2008.12.004.
43. Cukierman, E., and D.E. Bassi. 2010. Physico-mechanical aspects of extracellular matrix influences on tumorigenic behaviors. Semin. Cancer Biol. 20:139-145. http://dx.doi.org/10.1016/j.semcancer.2010.04.004.
44. Cuttler, A.S., R.J. LeClair, J.P. Stohn, Q. Wang, C.M. Sorenson, L. Liaw, and V. Lindner. 2011. Characterization of Pdgfrb-Cre transgenic mice reveals reduction of ROSA26 reporter activity in remodeling arteries. Genesis. 49:673-680. http://dx.doi.org/10.1002/dvg.20769.
45. Danø, K., N. Behrendt, G. Høyer-Hansen, M. Johnsen, L.R. Lund, M. Ploug, and J. Rømer. 2005. Plasminogen activation and cancer. Thromb. Haemost. 93:676-681.
46. Desmoulière, A., M. Redard, I. Darby, and G. Gabbiani. 1995. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol. 146:56-66.
47. Desmoulière, A., C. Guyot, and G. Gabbiani. 2004. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int. J. Dev. Biol. 48:509-517. http://dx.doi.org/10.1387/ijdb.041802ad.
48. Ding, N., R.T. Yu, N. Subramaniam, M.H. Sherman, C. Wilson, R. Rao, M. Leblanc, S. Coulter, M. He, C. Scott, et al. 2013. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 153:601-613. http://dx.doi.org/10.1016/j.cell.2013.03.028.
49. Diop-Frimpong, B., V.P. Chauhan, S. Krane, Y. Boucher, and R.K. Jain. 2011. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. USA. 108:2909-2914. http://dx.doi.org/10.1073/pnas.1018892108.
50. Direkze, N.C., K. Hodivala-Dilke, R. Jeffery, T. Hunt, R. Poulsom, D. Oukrif, M.R. Alison, and N.A. Wright. 2004. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 64:8492-8495. http://dx.doi.org/10.1158/0008-5472.CAN-04-1708.
51. Doherty, J.R., and J.L. Cleveland. 2013. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123:3685-3692. http://dx.doi.org/10.1172/JCI69741.
52. Domanska, U.M., H. Timmer-Bosscha, W.B. Nagengast, T.H. Oude Munnink, R.C. Kruizinga, H.J. Ananias, N.M. Kliphuis, G. Huls, E.G. De Vries, I.J. de Jong, and A.M. Walenkamp. 2012. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia. 14:709-718.
53. Duda, D.G., A.M. Duyverman, M. Kohno, M. Snuderl, E.J. Steller, D. Fukumura, and R.K. Jain. 2010. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. USA. 107:21677-21682. http://dx.doi.org/10.1073/pnas.1016234107.
54. Dufour, A., and C.M. Overall. 2013. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol. Sci. 34:233-242. http://dx.doi.org/10.1016/j.tips.2013.02.004.
55. Dvorak, H.F. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315:1650-1659. http://dx.doi.org/10.1056/NEJM198612253152606.
56. Eguchi, D., N. Ikenaga, K. Ohuchida, S. Kozono, L. Cui, K. Fujiwara, M. Fujino, T. Ohtsuka, K. Mizumoto, and M. Tanaka. 2013. Hypoxia enhances the interaction between pancreatic stellate cells and cancer cells via increased secretion of connective tissue growth factor. J. Surg. Res. 181:225-233. http://dx.doi.org/10.1016/j.jss.2012.06.051.
57. Erez, N., M. Truitt, P. Olson, S.T. Arron, and D. Hanahan. 2010. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner. Cancer Cell. 17:135-147. http://dx.doi.org/10.1016/j.ccr.2009.12.041.
58. Erkan, M., C.W. Michalski, S. Rieder, C. Reiser-Erkan, I. Abiatari, A. Kolb, N.A. Giese, I. Esposito, H. Friess, and J. Kleeff. 2008. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 6:1155-1161. http://dx.doi.org/10.1016/j.cgh.2008.05.006.
59. Erler, J.T., and V.M. Weaver. 2009. Three-dimensional context regulation of metastasis. Clin. Exp. Metastasis. 26:35-49. http://dx.doi.org/10 .1007/s10585-008-9209-8.
60. Farmer, P., H. Bonnefoi, P. Anderle, D. Cameron, P. Wirapati, V. Becette, S. André, M. Piccart, M. Campone, E. Brain, et al. 2009. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15:68-74. http://dx.doi.org/10.1038/nm.1908.
61. Feig, C., J.O. Jones, M. Kraman, R.J. Wells, A. Deonarine, D.S. Chan, C.M. Connell, E.W. Roberts, Q. Zhao, O.L. Caballero, et al. 2013. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA. 110:20212-20217. http://dx.doi.org/10.1073/pnas .1320318110.
62. Fidler, I.J., C. Wilmanns, A. Staroselsky, R. Radinsky, Z. Dong, and D. Fan. 1994. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev. 13:209-222. http://dx.doi.org/10.1007/BF00689637.
63. Flaberg, E., L. Markasz, G. Petranyi, G. Stuber, F. Dicso, N. Alchihabi, È. Oláh, I. Csízy, T. Józsa, O. Andrén, et al. 2011. High-throughput livecell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts. Int. J. Cancer. 128:2793-2802. http://dx.doi.org/10.1002/ijc.25612.
64. Flaherty, K.T., I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.J. O'Dwyer, R.J. Lee, J.F. Grippo, K. Nolop, and P.B. Chapman. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363:809-819. http://dx.doi.org/10.1056/NEJMoa1002011.
65. Forsberg, K., I. Valyi-Nagy, C.H. Heldin, M. Herlyn, and B. Westermark. 1993. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc. Natl. Acad. Sci. USA. 90:393-397. http://dx.doi.org/10.1073/pnas.90.2.393.
66. Frese, K.K., A. Neesse, N. Cook, T.E. Bapiro, M.P. Lolkema, D.I. Jodrell, and D.A. Tuveson. 2012. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2:260-269. http://dx.doi.org/10.1158/2159-8290 .CD-11-0242.
67. Fridman, R., G. Giaccone, T. Kanemoto, G.R. Martin, A.F. Gazdar, and J.L. Mulshine. 1990. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA. 87:6698-6702. http://dx.doi.org/10.1073/pnas.87.17.6698.
68. Froeling, F.E., C. Feig, C. Chelala, R. Dobson, C.E. Mein, D.A. Tuveson, H. Clevers, I.R. Hart, and H.M. Kocher. 2011. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology. 141:1486-1497: 1497.e14. http://dx.doi.org/10.1053/j.gastro.2011.06.047.
69. Gaggioli, C., S. Hooper, C. Hidalgo-Carcedo, R. Grosse, J.F. Marshall, K. Harrington, and E. Sahai. 2007. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 9:1392-1400. http://dx.doi.org/10.1038/ncb1658.
70. Gao, R., and D.R. Brigstock. 2005. Connective tissue growth factor (CCN2) in rat pancreatic stellate cell function: integrin α5β1 as a novel CCN2 receptor. Gastroenterology. 129:1019-1030. http://dx.doi.org/10.1053/j.gastro.2005.06.067.
71. Garin-Chesa, P., L.J. Old, and W.J. Rettig. 1990. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA. 87:7235-7239. http://dx .doi.org/10.1073/pnas.87.18.7235.
72. Giannoni, E., F. Bianchini, L. Masieri, S. Serni, E. Torre, L. Calorini, and P. Chiarugi. 2010. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 70:6945-6956. http://dx.doi.org/10 .1158/0008-5472.CAN-10-0785.
73. Giannoni, E., F. Bianchini, L. Calorini, and P. Chiarugi. 2011. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid. Redox Signal. 14:2361-2371. http://dx.doi.org/10.1089/ars .2010.3727.
74. Goetz, J.G., S. Minguet, I. Navarro-Lérida, J.J. Lazcano, R. Samaniego, E. Calvo, M. Tello, T. Osteso-Ibáñez, T. Pellinen, A. Echarri, et al. 2011. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell. 146:148-163. http://dx.doi.org/10.1016/j.cell.2011.05.040.
75. Gonda, T.A., A. Varro, T.C. Wang, and B. Tycko. 2010. Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy? Semin. Cell Dev. Biol. 21:2-10. http://dx.doi.org/10.1016/j.semcdb.2009.10.001.
76. Götte, M., and G.W. Yip. 2006. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 66:10233-10237. http://dx.doi.org/10.1158/0008-5472.CAN-06-1464.
77. Grivennikov, S.I., F.R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell. 140:883-899. http://dx.doi.org/10.1016/j.cell .2010.01.025.
78. Grum-Schwensen, B., J. Klingelhofer, C.H. Berg, C. El-Naaman, M. Grigorian, E. Lukanidin, and N. Ambartsumian. 2005. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. 65:3772-3780. http://dx.doi.org/10.1158/0008-5472 .CAN-04-4510.
79. Gu, J., H. Qian, L. Shen, X. Zhang, W. Zhu, L. Huang, Y. Yan, F. Mao, C. Zhao, Y. Shi, and W. Xu. 2012. Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-β/Smad pathway. PLoS ONE. 7:e52465. http://dx.doi.org/10.1371/journal.pone.0052465.
80. Guarino, M., B. Rubino, and G. Ballabio. 2007. The role of epithelialmesenchymal transition in cancer pathology. Pathology. 39:305-318. http://dx.doi.org/10.1080/00313020701329914.
81. Guerra, C., A.J. Schuhmacher, M. Cañamero, P.J. Grippo, L. Verdaguer, L. Pérez-Gallego, P. Dubus, E.P. Sandgren, and M. Barbacid. 2007. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 11:291-302. http://dx.doi.org/10.1016/j.ccr.2007.01.012.
82. Guido, C., D. Whitaker-Menezes, C. Capparelli, R. Balliet, Z. Lin, R.G. Pestell, A. Howell, S. Aquila, S. Andò, U. Martinez-Outschoorn, et al. 2012. Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production. Cell Cycle. 11:3019-3035. http://dx.doi.org/10.4161/cc.21384.
83. Guo, X., H. Oshima, T. Kitmura, M.M. Taketo, and M. Oshima. 2008. Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J. Biol. Chem. 283:19864-19871. http://dx.doi.org/10.1074/jbc.M800798200.
84. Hamada, S., A. Masamune, T. Takikawa, N. Suzuki, K. Kikuta, M. Hirota, H. Hamada, M. Kobune, K. Satoh, and T. Shimosegawa. 2012. Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 421:349-354. http://dx.doi.org/10.1016/j.bbrc.2012.04.014.
85. Hanahan, D., and R.A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell. 144:646-674. http://dx.doi.org/10.1016/j.cell.2011.02.013.
86. Hartel, M., F.F. Di Mola, A. Gardini, A. Zimmermann, P. Di Sebastiano, A. Guweidhi, P. Innocenti, T. Giese, N. Giese, M.W. Büchler, and H. Friess. 2004. Desmoplastic reaction influences pancreatic cancer growth behavior. World J. Surg. 28:818-825. http://dx.doi.org/10.1007/s00268-004-7147-4.
87. Hartmann, T.N., J.A. Burger, A. Glodek, N. Fujii, and M. Burger. 2005. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene. 24:4462-4471. http://dx.doi.org/10.1038/sj.onc.1208621.
88. Haubeiss, S., J.O. Schmid, T.E. Mürdter, M. Sonnenberg, G. Friedel, H. van der Kuip, and W.E. Aulitzky. 2010. Dasatinib reverses cancerassociated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol. Cancer. 9:168. http://dx.doi.org/10.1186/1476-4598-9-168.
89. Hawinkels, L.J., M. Paauwe, H.W. Verspaget, E. Wiercinska, J.M. van der Zon, K. van der Ploeg, P.J. Koelink, J.H. Lindeman, W. Mesker, P. ten Dijke, and C.F. Sier. 2014. Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts. Oncogene. 33:97-107. http://dx.doi.org/10.1038/onc.2012.536.
90. Hayward, S.W., Y. Wang, M. Cao, Y.K. Hom, B. Zhang, G.D. Grossfeld, D. Sudilovsky, and G.R. Cunha. 2001. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 61:8135-8142.
91. Herrera, M., A.B. Islam, A. Herrera, P. Martín, V. García, J. Silva, J.M. Garcia, C. Salas, I. Casal, A.G. de Herreros, et al. 2013. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin. Cancer Res. 19:5914-5926. http://dx.doi.org/10.1158/1078-0432.CCR-13-0694.
92. Hill, R., Y. Song, R.D. Cardiff, and T. Van Dyke. 2005. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 123:1001-1011. http://dx.doi.org/10.1016/j.cell.2005.09.030.
93. Hinz, B., G. Celetta, J.J. Tomasek, G. Gabbiani, and C. Chaponnier. 2001. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell. 12:2730-2741. http://dx.doi.org/10.1091/mbc.12.9.2730.
94. Hofheinz, R.D., S.E. al-Batran, F. Hartmann, G. Hartung, D. Jäger, C. Renner, P. Tanswell, U. Kunz, A. Amelsberg, H. Kuthan, and G. Stehle. 2003. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 26:44-48. http://dx.doi.org/10.1159/000069863.
95. Hooper, S., C. Gaggioli, and E. Sahai. 2010. A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion. Br. J. Cancer. 102:392-402. http://dx.doi.org/10.1038/sj.bjc.6605469.
96. Hosein, A.N., M. Wu, S.L. Arcand, S. Lavallée, J. Hébert, P.N. Tonin, and M. Basik. 2010. Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res. 70:5770-5777. http://dx.doi.org/10.1158/0008-5472.CAN-10-0673.
97. Hu, M., J. Yao, L. Cai, K.E. Bachman, F. van den Brûle, V. Velculescu, and K. Polyak. 2005. Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 37:899-905. http://dx.doi.org/10.1038/ng1596.
98. Hu, M., G. Peluffo, H. Chen, R. Gelman, S. Schnitt, and K. Polyak. 2009. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc. Natl. Acad. Sci. USA. 106:3372-3377. http://dx.doi.org/10.1073/pnas.0813306106.
99. Huang, S., R. Fang, J. Xu, S. Qiu, H. Zhang, J. Du, and S. Cai. 2011. Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug. J. Drug Target. 19:487-496. http://dx.doi.org/10.3109/1061186X.2010.511225.
100. Hwang, R.F., T. Moore, T. Arumugam, V. Ramachandran, K.D. Amos, A. Rivera, B. Ji, D.B. Evans, and C.D. Logsdon. 2008. Cancerassociated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68:918-926. http://dx.doi.org/10.1158/0008-5472.CAN-07-5714.
101. Iijima, J., K. Konno, and N. Itano. 2011. Inflammatory alterations of the extracellular matrix in the tumor microenvironment. Cancers (Basel). 3:3189-3205. http://dx.doi.org/10.3390/cancers3033189.
102. Ishii, G., T. Sangai, T. Oda, Y. Aoyagi, T. Hasebe, N. Kanomata, Y. Endoh, C. Okumura, Y. Okuhara, J. Magae, et al. 2003. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem. Biophys. Res. Commun. 309:232-240. http://dx.doi.org/10.1016/S0006-291X(03)01544-4.
103. Iwano, M., D. Plieth, T.M. Danoff, C. Xue, H. Okada, and E.G. Neilson. 2002. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110:341-350. http://dx.doi.org/10.1172/JCI0215518.
104. Jacobetz, M.A., D.S. Chan, A. Neesse, T.E. Bapiro, N. Cook, K.K. Frese, C. Feig, T. Nakagawa, M.E. Caldwell, H.I. Zecchini, et al. 2013. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 62:112-120. http://dx.doi .org/10.1136/gutjnl-2012-302529.
105. Jacobson, A., and J.L. Cunningham. 2012. Connective tissue growth factor in tumor pathogenesis. Fibrogenesis Tissue Repair. 5:S8. http://dx.doi .org/10.1186/1755-1536-5-S1-S8.
106. Jain, R.K. 1990. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 9:253-266. http://dx.doi .org/10.1007/BF00046364.
107. Jedeszko, C., B.C. Victor, I. Podgorski, and B.F. Sloane. 2009. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res. 69:9148-9155. http://dx.doi .org/10.1158/0008-5472.CAN-09-1043.
108. Jeon, E.S., H.J. Moon, M.J. Lee, H.Y. Song, Y.M. Kim, M. Cho, D.S. Suh, M.S. Yoon, C.L. Chang, J.S. Jung, and J.H. Kim. 2008. Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells. 26:789-797. http://dx.doi.org/10.1634/stemcells.2007-0742.
109. Jiang, L., T.A. Gonda, M.V. Gamble, M. Salas, V. Seshan, S. Tu, W.S. Twaddell, P. Hegyi, G. Lazar, I. Steele, et al. 2008. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res. 68:9900-9908. http://dx.doi.org/10.1158/0008-5472.CAN-08-1319.
110. Jung, D.W., Z.M. Che, J. Kim, K. Kim, K.Y. Kim, D. Williams, and J. Kim. 2010. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int. J. Cancer. 127:332-344.
111. Kadaba, R., H. Birke, J. Wang, S. Hooper, C.D. Andl, F. Di Maggio, E. Soylu, M. Ghallab, D. Bor, F.E. Froeling, et al. 2013. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J. Pathol. 230:107-117. http://dx.doi.org/10.1002/path.4172.
112. Kahlert, C., and R. Kalluri. 2013. Exosomes in tumor microenvironment influence cancer progression and metastasis. J. Mol. Med. 91:431-437. http://dx.doi.org/10.1007/s00109-013-1020-6.
113. Kalluri, R., and M. Zeisberg. 2006. Fibroblasts in cancer. Nat. Rev. Cancer. 6:392-401. http://dx.doi.org/10.1038/nrc1877.
114. Kano, M.R., Y. Bae, C. Iwata, Y. Morishita, M. Yashiro, M. Oka, T. Fujii, A. Komuro, K. Kiyono, M. Kaminishi, et al. 2007. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl. Acad. Sci. USA. 104:3460-3465. http://dx.doi.org/10.1073/pnas.0611660104.
115. Karnoub, A.E., A.B. Dash, A.P. Vo, A. Sullivan, M.W. Brooks, G.W. Bell, A.L. Richardson, K. Polyak, R. Tubo, and R.A. Weinberg. 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 449:557-563. http://dx.doi.org/10.1038/nature06188.
116. Kawase, A., G. Ishii, K. Nagai, T. Ito, T. Nagano, Y. Murata, T. Hishida, M. Nishimura, J. Yoshida, K. Suzuki, and A. Ochiai. 2008. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int. J. Cancer. 123:1053-1059. http://dx.doi.org/10.1002/ijc.23611.
117. Kidd, S., E. Spaeth, K. Watson, J. Burks, H. Lu, A. Klopp, M. Andreeff, and F.C. Marini. 2012. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS ONE. 7:e30563. http://dx.doi.org/10.1371/journal.pone.0030563.
118. Kikuta, K., A. Masamune, T. Watanabe, H. Ariga, H. Itoh, S. Hamada, K. Satoh, S. Egawa, M. Unno, and T. Shimosegawa. 2010. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 403:380-384. http://dx.doi.org/10 .1016/j.bbrc.2010.11.040.
119. Kinugasa, Y., T. Matsui, and N. Takakura. 2014. CD44 expressed on cancerassociated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells. 32:145-156. http://dx.doi.org/10.1002/stem.1556.
120. Kobayashi, N., S. Miyoshi, T. Mikami, H. Koyama, M. Kitazawa, M. Takeoka, K. Sano, J. Amano, Z. Isogai, S. Niida, et al. 2010. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res. 70:7073-7083. http://dx.doi.org/10.1158/0008-5472.CAN-09-4687.
121. Y., A. Acar, E.N. Eaton, K.T. Mellody, C. Scheel, I. Ben-Porath, T.T. Onder, Z.C. Wang, A.L. Richardson, R.A. Weinberg, and A. Orimo. 2010. Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. USA. 107:20009-20014. http://dx.doi.org/10.1073/pnas.1013805107.
122. Kordes, C., I. Sawitza, and D. Häussinger. 2009. Hepatic and pancreatic stellate cells in focus. Biol. Chem. 390:1003-1012. http://dx.doi.org/10.1515/BC.2009.121.
123. Koukourakis, M.I., A. Giatromanolaki, A.L. Harris, and E. Sivridis. 2006. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 66:632-637. http://dx.doi.org/10.1158/0008-5472.CAN-05-3260.
124. Kraman, M., P.J. Bambrough, J.N. Arnold, E.W. Roberts, L. Magiera, J.O. Jones, A. Gopinathan, D.A. Tuveson, and D.T. Fearon. 2010. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science. 330:827-830. http://dx.doi.org/10 .1126/science.1195300.
125. Krtolica, A., S. Parrinello, S. Lockett, P.Y. Desprez, and J. Campisi. 2001. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. USA. 98:12072-12077. http://dx.doi.org/10.1073/pnas.211053698.
126. Kuperwasser, C., T. Chavarria, M. Wu, G. Magrane, J.W. Gray, L. Carey, A. Richardson, and R.A. Weinberg. 2004. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. USA. 101:4966-4971. http://dx.doi.org/10.1073/pnas.0401064101.
127. Kurose, K., K. Gilley, S. Matsumoto, P.H. Watson, X.P. Zhou, and C. Eng. 2002. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet. 32:355-357. http://dx.doi.org/10.1038/ng1013.
128. Kwabi-Addo, B., M. Ozen, and M. Ittmann. 2004. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr. Relat. Cancer. 11:709-724. http://dx.doi.org/10.1677/erc.1.00535.
129. LeBeau, A.M., W.N. Brennen, S. Aggarwal, and S.R. Denmeade. 2009. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol. Cancer Ther. 8:1378-1386. http://dx.doi .org/10.1158/1535-7163.MCT-08-1170.
130. Lederle, W., B. Hartenstein, A. Meides, H. Kunzelmann, Z. Werb, P. Angel, and M.M. Mueller. 2010. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis. 31:1175-1184. http://dx.doi.org/10.1093/carcin/bgp248.
131. Lee, J., M. Fassnacht, S. Nair, D. Boczkowski, and E. Gilboa. 2005. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 65:11156-11163. http://dx.doi.org/10.1158/0008-5472.CAN-05-2805.
132. Lee, M.J., A.S. Ye, A.K. Gardino, A.M. Heijink, P.K. Sorger, G. MacBeath, and M.B. Yaffe. 2012. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 149:780-794. http://dx.doi.org/10.1016/j.cell.2012.03.031.
133. Lemons, J.M., X.J. Feng, B.D. Bennett, A. Legesse-Miller, E.L. Johnson, I. Raitman, E.A. Pollina, H.A. Rabitz, J.D. Rabinowitz, and H.A. Coller. 2010. Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol. 8:e1000514. http://dx.doi.org/10.1371/journal.pbio.1000514.
134. Levental, K.R., H. Yu, L. Kass, J.N. Lakins, M. Egeblad, J.T. Erler, S.F. Fong, K. Csiszar, A. Giaccia, W. Weninger, et al. 2009. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 139:891-906. http://dx.doi.org/10.1016/j.cell.2009.10.027.
135. Li, H.J., F. Reinhardt, H.R. Herschman, and R.A. Weinberg. 2012a. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov. 2:840-855. http://dx.doi.org/10.1158/2159-8290.CD-12-0101.
136. Li, T., Y. Yang, X. Hua, G. Wang, W. Liu, C. Jia, Y. Tai, Q. Zhang, and G. Chen. 2012b. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett. 318:154-161. http://dx.doi.org/10.1016/j.canlet.2011.12.020.
137. Li, X., Q. Ma, Q. Xu, H. Liu, J. Lei, W. Duan, K. Bhat, F. Wang, E. Wu, and Z. Wang. 2012c. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett. 322:169-176. http://dx.doi.org/10.1016/j.canlet.2012.02.035.
138. Liao, D., Y. Luo, D. Markowitz, R. Xiang, and R.A. Reisfeld. 2009. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE. 4:e7965. http://dx.doi.org/10.1371/journal.pone.0007965.
139. Lieubeau, B., L. Garrigue, I. Barbieux, K. Meflah, and M. Gregoire. 1994. The role of transforming growth factor beta 1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res. 54:6526-6532.
140. Liu, J., S. Liao, B. Diop-Frimpong, W. Chen, S. Goel, K. Naxerova, M. Ancukiewicz, Y. Boucher, R.K. Jain, and L. Xu. 2012. TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc. Natl. Acad. Sci. USA. 109:16618-16623. http://dx.doi.org/10.1073/pnas.1117610109.
141. Liu, S., C. Ginestier, S.J. Ou, S.G. Clouthier, S.H. Patel, F. Monville, H. Korkaya, A. Heath, J. Dutcher, C.G. Kleer, et al. 2011. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 71:614-624. http://dx.doi.org/10.1158/0008-5472.CAN-10-0538.
142. Loeffler, M., J.A. Krüger, A.G. Niethammer, and R.A. Reisfeld. 2006. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 116:1955-1962. http://dx.doi.org/10.1172/JCI26532.
143. Löhr, M., C. Schmidt, J. Ringel, M. Kluth, P. Müller, H. Nizze, and R. Jesnowski. 2001. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61:550-555.
144. Lotti, F., A.M. Jarrar, R.K. Pai, M. Hitomi, J. Lathia, A. Mace, G.A. Gantt Jr., K. Sukhdeo, J. DeVecchio, A. Vasanji, et al. 2013. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancerinitiating cells by IL-17A. J. Exp. Med. 210:2851-2872. http://dx.doi.org/10.1084/jem.20131195.
145. Luga, V., L. Zhang, A.M. Viloria-Petit, A.A. Ogunjimi, M.R. Inanlou, E. Chiu, M. Buchanan, A.N. Hosein, M. Basik, and J.L. Wrana. 2012. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 151:1542-1556. http://dx.doi .org/10.1016/j.cell.2012.11.024.
146. Mace, T.A., Z. Ameen, A. Collins, S. Wojcik, M. Mair, G.S. Young, J.R. Fuchs, T.D. Eubank, W.L. Frankel, T. Bekaii-Saab, et al. 2013. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 73:3007-3018. http://dx.doi.org/10.1158/0008-5472.CAN-12-4601.
147. Madar, S., R. Brosh, Y. Buganim, O. Ezra, I. Goldstein, H. Solomon, I. Kogan, N. Goldfinger, H. Klocker, and V. Rotter. 2009. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis. 30:20-27. http://dx.doi.org/10.1093/carcin/bgn232.
148. Maeshima, A.M., T. Niki, A. Maeshima, T. Yamada, H. Kondo, and Y. Matsuno. 2002. Modified scar grade: a prognostic indicator in small peripheral lung adenocarcinoma. Cancer. 95:2546-2554. http://dx.doi .org/10.1002/cncr.11006.
149. Malanchi, I., A. Santamaria-Martínez, E. Susanto, H. Peng, H.A. Lehr, J.F. Delaloye, and J. Huelsken. 2012. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 481:85-89. http://dx.doi.org/10.1038/nature10694.
150. Martinez-Outschoorn, U.E., Z. Lin, C. Trimmer, N. Flomenberg, C. Wang, S. Pavlides, R.G. Pestell, A. Howell, F. Sotgia, and M.P. Lisanti. 2011. Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle. 10:2504-2520. http://dx.doi.org/10.4161/cc.10.15.16585.
151. Masamune, A., S. Hamada, K. Kikuta, T. Takikawa, S. Miura, E. Nakano, and T. Shimosegawa. 2013. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand. J. Gastroenterol. 48:602-609. http://dx.doi .org/10.3109/00365521.2013.777776.
152. Masamune, A., E. Nakano, S. Hamada, T. Takikawa, N. Yoshida, and T. Shimosegawa. 2014. Alteration of the microRNA expression profile during the activation of pancreatic stellate cells. Scand. J. Gastroenterol. 49:323-331. http://dx.doi.org/10.3109/00365521.2013.876447.
153. Matsuda, Y., S. Kure, and T. Ishiwata. 2012. Nestin and other putative cancer stem cell markers in pancreatic cancer. Med. Mol. Morphol. 45:59-65. http://dx.doi.org/10.1007/s00795-012-0571-x.
154. McMillin, D.W., J.M. Negri, and C.S. Mitsiades. 2013. The role of tumourstromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12:217-228. http://dx.doi.org/10 .1038/nrd3870.
155. Meads, M.B., R.A. Gatenby, and W.S. Dalton. 2009. Environmentmediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer. 9:665-674. http://dx.doi.org/10.1038/nrc2714.
156. Mishra, P.J., P.J. Mishra, R. Humeniuk, D.J. Medina, G. Alexe, J.P. Mesirov, S. Ganesan, J.W. Glod, and D. Banerjee. 2008. Carcinomaassociated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 68:4331-4339. http://dx.doi.org/10.1158/0008-5472 .CAN-08-0943.
157. Mitra, A.K., M. Zillhardt, Y. Hua, P. Tiwari, A.E. Murmann, M.E. Peter, and E. Lengyel. 2012. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2:1100-1108. http://dx.doi.org/10.1158/2159-8290.CD-12-0206.
158. Miyamoto, H., T. Murakami, K. Tsuchida, H. Sugino, H. Miyake, and S. Tashiro. 2004. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas. 28:38-44. http://dx.doi.org/10.1097/00006676-200401000-00006.
159. Mullamitha, S.A., N.C. Ton, G.J. Parker, A. Jackson, P.J. Julyan, C. Roberts, G.A. Buonaccorsi, Y. Watson, K. Davies, S. Cheung, et al. 2007. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res. 13:2128-2135. http://dx.doi.org/10.1158/1078-0432.CCR-06-2779.
160. Muranen, T., L.M. Selfors, D.T. Worster, M.P. Iwanicki, L. Song, F.C. Morales, S. Gao, G.B. Mills, and J.S. Brugge. 2012. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 21:227-239. http://dx.doi.org/10.1016/j.ccr.2011.12.024.
161. Musumeci, M., V. Coppola, A. Addario, M. Patrizii, M. Maugeri-Saccà, L. Memeo, C. Colarossi, F. Francescangeli, M. Biffoni, D. Collura, et al. 2011. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 30:4231-4242. http://dx.doi.org/10.1038/onc.2011.140.
162. Nakagawa, H., S. Liyanarachchi, R.V. Davuluri, H. Auer, E.W. Martin Jr., A. de la Chapelle, and W.L. Frankel. 2004. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene. 23:7366-7377. http://dx.doi.org/10.1038/sj.onc.1208013.
163. Nakai, Y., H. Isayama, H. Ijichi, T. Sasaki, N. Sasahira, K. Hirano, H. Kogure, K. Kawakubo, H. Yagioka, Y. Yashima, et al. 2010. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer. 103:1644-1648. http://dx.doi.org/10.1038/sj.bjc.6605955.
164. Neesse, A., P. Michl, K.K. Frese, C. Feig, N. Cook, M.A. Jacobetz, M.P. Lolkema, M. Buchholz, K.P. Olive, T.M. Gress, and D.A. Tuveson. 2011. Stromal biology and therapy in pancreatic cancer. Gut. 60:861-868. http://dx.doi.org/10.1136/gut.2010.226092.
165. Neesse, A., K.K. Frese, T.E. Bapiro, T. Nakagawa, M.D. Sternlicht, T.W. Seeley, C. Pilarsky, D.I. Jodrell, S.M. Spong, and D.A. Tuveson. 2013. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc. Natl. Acad. Sci. USA. 110:12325-12330. http://dx.doi.org/10.1073/pnas.1300415110.
166. Neesse, A., K.K. Frese, D.S. Chan, T.E. Bapiro, W.J. Howat, F.M. Richards, V. Ellenrieder, D.I. Jodrell, and D.A. Tuveson. 2014. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut. 63:974-983. http://dx.doi.org/10.1136/gutjnl-2013-305559.
167. Noskova, V., S. Ahmadi, E. Asander, and B. Casslén. 2009. Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms. Gynecol. Oncol. 115:121-126. http://dx.doi.org/10.1016/j.ygyno.2009.06.026.
168. O'Connell, J.T., H. Sugimoto, V.G. Cooke, B.A. MacDonald, A.I. Mehta, V.S. LeBleu, R. Dewar, R.M. Rocha, R.R. Brentani, M.B. Resnick, et al. 2011. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc. Natl. Acad. Sci. USA. 108:16002-16007. http://dx.doi.org/10.1073/pnas.1109493108.
169. Ohuchida, K., K. Mizumoto, M. Murakami, L.W. Qian, N. Sato, E. Nagai, K. Matsumoto, T. Nakamura, and M. Tanaka. 2004. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. 64:3215-3222. http://dx.doi.org/10.1158/0008-5472.CAN-03-2464.
170. Okada, H., T.M. Danoff, R. Kalluri, and E.G. Neilson. 1997. Early role of Fsp1 in epithelial-mesenchymal transformation. Am. J. Physiol. 273:F563-F574.
171. Olive, K.P., M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M.A. Goldgraben, M.E. Caldwell, D. Allard, et al. 2009. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 324:1457-1461. http://dx.doi.org/10.1126/science.1171362.
172. Olumi, A.F., G.D. Grossfeld, S.W. Hayward, P.R. Carroll, T.D. Tlsty, and G.R. Cunha. 1999. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59: 5002-5011.
173. Orimo, A., and R.A. Weinberg. 2007. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol. Ther. 6:618-619. http://dx.doi.org/10.4161/cbt.6.4.4255.
174. Orimo, A., Y. Tomioka, Y. Shimizu, M. Sato, S. Oigawa, K. Kamata, Y. Nogi, S. Inoue, M. Takahashi, T. Hata, and M. Muramatsu. 2001. Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin. Cancer Res. 7:3097-3105.
175. Orimo, A., P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson, and R.A. Weinberg. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121:335-348. http://dx.doi.org/10.1016/j.cell.2005.02.034.
176. Ostermann, E., P. Garin-Chesa, K.H. Heider, M. Kalat, H. Lamche, C. Puri, D. Kerjaschki, W.J. Rettig, and G.R. Adolf. 2008. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 14:4584-4592. http://dx.doi.org/10 .1158/1078-0432.CCR-07-5211.
177. Österreicher, C.H., M. Penz-Österreicher, S.I. Grivennikov, M. Guma, E.K. Koltsova, C. Datz, R. Sasik, G. Hardiman, M. Karin, and D.A. Brenner. 2011. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc. Natl. Acad. Sci. USA. 108:308-313. http://dx.doi.org/10.1073/pnas.1017547108.
178. Özdemir, B.C., T. Pentcheva-Hoang, J.L. Carstens, X. Zheng, C.C. Wu, T.R. Simpson, H. Laklai, H. Sugimoto, C. Kahlert, S.V. Novitskiy, et al. 2014. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 25:719-734. http://dx.doi.org/10.1016/j.ccr.2014.04.005.
179. Paget, S. 1889. The distribution of secondary growths in cancer of the breast. Lancet. 133:571-573. http://dx.doi.org/10.1016/S0140-6736(00)49915-0.
180. Park, C.C., H. Zhang, M. Pallavicini, J.W. Gray, F. Baehner, C.J. Park, and M.J. Bissell. 2006. β1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 66:1526-1535. http://dx.doi.org/10.1158/0008-5472.CAN-05-3071.
181. Park, C.C., H.J. Zhang, E.S. Yao, C.J. Park, and M.J. Bissell. 2008. β1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 68:4398-4405. http://dx.doi.org/10.1158/0008-5472.CAN-07-6390.
182. Patocs, A., L. Zhang, Y. Xu, F. Weber, T. Caldes, G.L. Mutter, P. Platzer, and C. Eng. 2007. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N. Engl. J. Med. 357:2543-2551. http://dx.doi.org/10.1056/NEJMoa071825.
183. Paunescu, V., F.M. Bojin, C.A. Tatu, O.I. Gavriliuc, A. Rosca, A.T. Gruia, G. Tanasie, C. Bunu, D. Crisnic, M. Gherghiceanu, et al. 2011. Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J. Cell. Mol. Med. 15:635-646. http://dx.doi.org/10.1111/j.1582-4934.2010.01044.x.
184. Pavlides, S., D. Whitaker-Menezes, R. Castello-Cros, N. Flomenberg, A.K. Witkiewicz, P.G. Frank, M.C. Casimiro, C. Wang, P. Fortina, S. Addya, et al. 2009. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 8:3984-4001. http://dx.doi.org/10.4161/cc.8.23.10238.
185. Peek, R.M. Jr., and J.E. Crabtree. 2006. Helicobacter infection and gastric neoplasia. J. Pathol. 208:233-248. http://dx.doi.org/10.1002/path.1868.
186. Peruzzi, B., and D.P. Bottaro. 2006. Targeting the c-Met signaling pathway in cancer. Clin. Cancer Res. 12:3657-3660. http://dx.doi.org/10.1158/1078-0432.CCR-06-0818.
187. Pickup, M., S. Novitskiy, and H.L. Moses. 2013a. The roles of TGFβ in the tumour microenvironment. Nat. Rev. Cancer. 13:788-799. http://dx.doi.org/10.1038/nrc3603.
188. Pickup, M.W., H. Laklai, I. Acerbi, P. Owens, A.E. Gorska, A. Chytil, M. Aakre, V.M. Weaver, and H.L. Moses. 2013b. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas. Cancer Res. 73:5336-5346. http://dx.doi .org/10.1158/0008-5472.CAN-13-0012.
189. Pietras, K., and A. Ostman. 2010. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316:1324-1331. http://dx.doi.org/10.1016/j.yexcr.2010.02.045.
190. Pietras, K., J. Pahler, G. Bergers, and D. Hanahan. 2008. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5:e19. http://dx.doi.org/10.1371/journal.pmed.0050019.
191. Pikarsky, E., R.M. Porat, I. Stein, R. Abramovitch, S. Amit, S. Kasem, E. Gutkovich-Pyest, S. Urieli-Shoval, E. Galun, and Y. Ben-Neriah. 2004. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461-466. http://dx.doi.org/10.1038/nature02924.
192. Polito, A., and R. Reynolds. 2005. NG2-expressing cells as oligodendrocyte progenitors in the normal and demyelinated adult central nervous system. J. Anat. 207:707-716. http://dx.doi.org/10.1111/j.1469-7580.2005.00454.x.
193. Poulsom, R., M. Pignatelli, W.G. Stetler-Stevenson, L.A. Liotta, P.A. Wright, R.E. Jeffery, J.M. Longcroft, L. Rogers, and G.W. Stamp. 1992. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am. J. Pathol. 141:389-396.
194. Provenzano, P.P., C. Cuevas, A.E. Chang, V.K. Goel, D.D. Von Hoff, and S.R. Hingorani. 2012. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 21:418-429. http://dx.doi.org/10.1016/j.ccr.2012.01.007.
195. Qiu, W., M. Hu, A. Sridhar, K. Opeskin, S. Fox, M. Shipitsin, M. Trivett, E.R. Thompson, M. Ramakrishna, K.L. Gorringe, et al. 2008. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat. Genet. 40:650-655. http://dx.doi.org/10.1038/ng.117.
196. Qu, C.F., E.Y. Song, Y. Li, S.M. Rizvi, C. Raja, R. Smith, A. Morgenstern, C. Apostolidis, and B.J. Allen. 2005. Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin. Exp. Metastasis. 22:575-586. http://dx.doi.org/10.1007/s10585-005-5788-9.
197. Quante, M., S.P. Tu, H. Tomita, T. Gonda, S.S. Wang, S. Takashi, G.H. Baik, W. Shibata, B. Diprete, K.S. Betz, et al. 2011. Bone marrowderived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 19:257-272. http://dx.doi .org/10.1016/j.ccr.2011.01.020.
198. Räsänen, K., and A. Vaheri. 2010. Activation of fibroblasts in cancer stroma. Exp. Cell Res. 316:2713-2722. http://dx.doi.org/10.1016/j.yexcr.2010.04.032.
199. Reardon, D.A., K.L. Fink, T. Mikkelsen, T.F. Cloughesy, A. O'Neill, S. Plotkin, M. Glantz, P. Ravin, J.J. Raizer, K.M. Rich, et al. 2008. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycineaspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26:5610-5617. http://dx.doi.org/10.1200/JCO.2008.16.7510.
200. Rhim, A.D., P.E. Oberstein, D.H. Thomas, E.T. Mirek, C.F. Palermo, S.A. Sastra, E.N. Dekleva, T. Saunders, C.P. Becerra, I.W. Tattersall, et al. 2014. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 25:735-747. http://dx.doi.org/10.1016/j.ccr.2014.04.021.
201. Roberts, E.W., A. Deonarine, J.O. Jones, A.E. Denton, C. Feig, S.K. Lyons, M. Espeli, M. Kraman, B. McKenna, R.J. Wells, et al. 2013. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 210:1137-1151. http://dx.doi.org/10.1084/jem.20122344.
202. Rønnov-Jessen, L., and O.W. Petersen. 1993. Induction of α-smooth muscle actin by transforming growth factor-β1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Invest. 68:696-707.
203. Rønnov-Jessen, L., and O.W. Petersen. 1996. A function for filamentous α-smooth muscle actin: retardation of motility in fibroblasts. J. Cell Biol. 134:67-80. http://dx.doi.org/10.1083/jcb.134.1.67.
204. Royal, R.E., C. Levy, K. Turner, A. Mathur, M. Hughes, U.S. Kammula, R.M. Sherry, S.L. Topalian, J.C. Yang, I. Lowy, and S.A. Rosenberg. 2010. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33:828-833. http://dx.doi.org/10.1097/CJI.0b013e3181eec14c.
205. Saadi, A., N.B. Shannon, P. Lao-Sirieix, M. O'Donovan, E. Walker, N.J. Clemons, J.S. Hardwick, C. Zhang, M. Das, V. Save, et al. 2010. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc. Natl. Acad. Sci. USA. 107:2177-2182. http://dx.doi.org/10.1073/pnas.0909797107.
206. Sakurai, T., M. Kudo, N. Fukuta, T. Nakatani, M. Kimura, A.M. Park, and H. Munakata. 2011. Involvement of angiotensin II and reactive oxygen species in pancreatic fibrosis. Pancreatology. 11:7-13. http://dx.doi.org/10.1159/000323478.
207. Santos, A.M., J. Jung, N. Aziz, J.L. Kissil, and E. Puré. 2009. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119:3613-3625. http://dx.doi.org/10.1172/JCI38988.
208. Sanz-Moreno, V., C. Gaggioli, M. Yeo, J. Albrengues, F. Wallberg, A. Viros, S. Hooper, R. Mitter, C.C. Féral, M. Cook, et al. 2011. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell. 20:229-245. http://dx.doi .org/10.1016/j.ccr.2011.06.018.
209. Sato, N., N. Maehara, and M. Goggins. 2004. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res. 64:6950-6956. http://dx.doi.org/10.1158/0008-5472.CAN-04-0677.
210. Scanlan, M.J., B.K. Raj, B. Calvo, P. Garin-Chesa, M.P. Sanz-Moncasi, J.H. Healey, L.J. Old, and W.J. Rettig. 1994. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. USA. 91:5657-5661. http://dx.doi.org/10.1073/pnas.91.12.5657.
211. Scott, A.M., G. Wiseman, S. Welt, A. Adjei, F.T. Lee, W. Hopkins, C.R. Divgi, L.H. Hanson, P. Mitchell, D.N. Gansen, et al. 2003. A Phase I doseescalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9: 1639-1647.
212. Serini, G., M.L. Bochaton-Piallat, P. Ropraz, A. Geinoz, L. Borsi, L. Zardi, and G. Gabbiani. 1998. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1. J. Cell Biol. 142:873-881. http://dx.doi.org/10.1083/jcb.142.3.873.
213. Sethi, T., R.C. Rintoul, S.M. Moore, A.C. MacKinnon, D. Salter, C. Choo, E.R. Chilvers, I. Dransfield, S.C. Donnelly, R. Strieter, and C. Haslett. 1999. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5:662-668. http://dx.doi.org/10.1038/9511.
214. Shao, Z.M., M. Nguyen, and S.H. Barsky. 2000. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene. 19:4337-4345. http://dx .doi.org/10.1038/sj.onc.1203785.
215. Sherman-Baust, C.A., A.T. Weeraratna, L.B. Rangel, E.S. Pizer, K.R. Cho, D.R. Schwartz, T. Shock, and P.J. Morin. 2003. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell. 3:377-386. http://dx.doi.org/10.1016/S1535-6108(03)00058-8.
216. Shimoda, M., K.T. Mellody, and A. Orimo. 2010. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin. Cell Dev. Biol. 21:19-25. http://dx.doi.org/10.1016/j.semcdb .2009.10.002.
217. Singh, S., S.R. Ross, M. Acena, D.A. Rowley, and H. Schreiber. 1992. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175:139-146. http://dx.doi.org/10.1084/jem.175.1.139.
218. Singh, S., S.K. Srivastava, A. Bhardwaj, L.B. Owen, and A.P. Singh. 2010. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br. J. Cancer. 103:1671-1679. http://dx.doi.org/10.1038/sj.bjc.6605968.
219. Smith, N.R., D. Baker, M. Farren, A. Pommier, R. Swann, X. Wang, S. Mistry, K. McDaid, J. Kendrew, C. Womack, et al. 2013. Tumor stromal architecture can define the intrinsic tumor response to VEGFtargeted therapy. Clin. Cancer Res. 19:6943-6956. http://dx.doi.org/10 .1158/1078-0432.CCR-13-1637.
220. Sosman, J.A., K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, J.S. Weber, G.A. McArthur, T.E. Hutson, S.J. Moschos, K.T. Flaherty, et al. 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366:707-714. http://dx.doi.org/10.1056/NEJMoa1112302.
221. Sounni, N.E., K. Dehne, L. van Kempen, M. Egeblad, N.I. Affara, I. Cuevas, J. Wiesen, S. Junankar, L. Korets, J. Lee, et al. 2010. Stromal regulation of vessel stability by MMP14 and TGFβ. Dis. Model. Mech. 3:317-332. http://dx.doi.org/10.1242/dmm.003863.
222. Sternlicht, M.D., A. Lochter, C.J. Sympson, B. Huey, J.P. Rougier, J.W. Gray, D. Pinkel, M.J. Bissell, and Z. Werb. 1999. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 98:137-146. http://dx.doi.org/10.1016/S0092-8674(00)81009-0.
223. Stetler-Stevenson, W.G., S. Aznavoorian, and L.A. Liotta. 1993. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9:541-573. http://dx.doi.org/10.1146/annurev .cb.09.110193.002545.
224. Stoker, M.G., M. Shearer, and C. O'Neill. 1966. Growth inhibition of polyoma-transformed cells by contact with static normal fibroblasts. J. Cell Sci. 1:297-310.
225. Straussman, R., T. Morikawa, K. Shee, M. Barzily-Rokni, Z.R. Qian, J. Du, A. Davis, M.M. Mongare, J. Gould, D.T. Frederick, et al. 2012. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487:500-504. http://dx.doi.org/10.1038/nature11183.
226. Strutz, F., H. Okada, C.W. Lo, T. Danoff, R.L. Carone, J.E. Tomaszewski, and E.G. Neilson. 1995. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 130:393-405. http://dx.doi.org/10.1083/jcb.130.2.393.
227. Strutz, F., M. Zeisberg, B. Hemmerlein, B. Sattler, K. Hummel, V. Becker, and G.A. Müller. 2000. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int. 57:1521-1538. http://dx.doi.org/10.1046/j.1523-1755.2000.00997.x.
228. Sugimoto, H., T.M. Mundel, M.W. Kieran, and R. Kalluri. 2006. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 5:1640-1646. http://dx.doi.org/10.4161/cbt.5.12.3354.
229. Sun, Y., J. Campisi, C. Higano, T.M. Beer, P. Porter, I. Coleman, L. True, and P.S. Nelson. 2012. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18:1359-1368. http://dx.doi.org/10.1038/nm.2890.
230. Teicher, B.A., T.S. Herman, S.A. Holden, Y.Y. Wang, M.R. Pfeffer, J.W. Crawford, and E. Frei III. 1990. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science. 247:1457-1461. http://dx.doi.org/10.1126/science.2108497.
231. Thayer, S.P., M.P. di Magliano, P.W. Heiser, C.M. Nielsen, D.J. Roberts, G.Y. Lauwers, Y.P. Qi, S. Gysin, C. Fernández-del Castillo, V. Yajnik, et al. 2003. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 425:851-856. http://dx.doi.org/10.1038/nature02009.
232. Tomasek, J.J., G. Gabbiani, B. Hinz, C. Chaponnier, and R.A. Brown. 2002. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3:349-363. http://dx.doi.org/10.1038/nrm809.
233. Torres, S., R.A. Bartolomé, M. Mendes, R. Barderas, M.J. Fernandez-Aceñero, A. Peláez-García, C. Peña, M. Lopez-Lucendo, R. Villar-Vázquez, A.G. de Herreros, et al. 2013. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin. Cancer Res. 19:6006-6019. http://dx.doi.org/10.1158/1078-0432.CCR-13-1130.
234. Toullec, A., D. Gerald, G. Despouy, B. Bourachot, M. Cardon, S. Lefort, M. Richardson, G. Rigaill, M.C. Parrini, C. Lucchesi, et al. 2010. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med. 2:211-230. http://dx.doi.org/10.1002/emmm.201000073.
235. Trimboli, A.J., C.Z. Cantemir-Stone, F. Li, J.A. Wallace, A. Merchant, N. Creasap, J.C. Thompson, E. Caserta, H. Wang, J.L. Chong, et al. 2009. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature. 461:1084-1091. http://dx.doi.org/10.1038/nature08486.
236. Tsujino, T., I. Seshimo, H. Yamamoto, C.Y. Ngan, K. Ezumi, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, and M. Monden. 2007. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin. Cancer Res. 13:2082-2090. http://dx.doi.org/10.1158/1078-0432.CCR-06-2191.
237. Vermeulen, L., F. De Sousa e Melo, M. van der Heijden, K. Cameron, J.H. de Jong, T. Borovski, J.B. Tuynman, M. Todaro, C. Merz, H. Rodermond, et al. 2010. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12:468-476. http://dx.doi.org/10.1038/ncb2048.
238. Vicent, S., L.C. Sayles, D. Vaka, P. Khatri, O. Gevaert, R. Chen, Y. Zheng, A.K. Gillespie, N. Clarke, Y. Xu, et al. 2012. Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 72:5744-5756. http://dx.doi.org/10.1158/0008-5472.CAN-12-1097.
239. Von Hoff, D.D., R.K. Ramanathan, M.J. Borad, D.A. Laheru, L.S. Smith, T.E. Wood, R.L. Korn, N. Desai, V. Trieu, J.L. Iglesias, et al. 2011. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29:4548-4554. http://dx.doi.org/10.1200/JCO.2011.36.5742.
240. Vosseler, S., W. Lederle, K. Airola, E. Obermueller, N.E. Fusenig, and M.M. Mueller. 2009. Distinct progression-associated expression of tumor and stromal MMPs in HaCaT skin SCCs correlates with onset of invasion. Int. J. Cancer. 125:2296-2306. http://dx.doi.org/10.1002/ijc.24589.
241. Walter, K., N. Omura, S.M. Hong, M. Griffith, and M. Goggins. 2008. Pancreatic cancer associated fibroblasts display normal allelotypes. Cancer Biol. Ther. 7:882-888. http://dx.doi.org/10.4161/cbt.7.6.5869.
242. Wang, X.M., D.M. Yu, G.W. McCaughan, and M.D. Gorrell. 2005. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology. 42:935-945. http://dx.doi.org/10.1002/hep.20853.
243. Wang, Z., Q. Ma, Q. Liu, H. Yu, L. Zhao, S. Shen, and J. Yao. 2008. Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br. J. Cancer. 99:1695-1703. http://dx.doi.org/10.1038/sj.bjc.6604745.
244. Wang, W., Q. Li, T. Yamada, K. Matsumoto, I. Matsumoto, M. Oda, G. Watanabe, Y. Kayano, Y. Nishioka, S. Sone, and S. Yano. 2009a. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 15:6630-6638. http://dx.doi.org/10.1158/1078-0432.CCR-09-1001.
245. Wang, Z., Y. Li, D. Kong, S. Banerjee, A. Ahmad, A.S. Azmi, S. Ali, J.L. Abbruzzese, G.E. Gallick, and F.H. Sarkar. 2009b. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 69:2400-2407. http://dx.doi.org/10.1158/0008-5472.CAN-08-4312.
246. Wang, J., G. Ying, J. Wang, Y. Jung, J. Lu, J. Zhu, K.J. Pienta, and R.S. Taichman. 2010. Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res. 70:471-480. http://dx.doi .org/10.1158/0008-5472.CAN-09-2863.
247. Webber, J., R. Steadman, M.D. Mason, Z. Tabi, and A. Clayton. 2010. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70:9621-9630. http://dx.doi.org/10.1158/0008-5472.CAN-10-1722.
248. Weissmueller, S., E. Manchado, M. Saborowski, J.P. Morris IV, E. Wagenblast, C.A. Davis, S.H. Moon, N.T. Pfister, D.F. Tschaharganeh, T. Kitzing, et al. 2014. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell. 157:382-394. http://dx.doi.org/10.1016/j.cell.2014.01.066.
249. Wen, J., K. Matsumoto, N. Taniura, D. Tomioka, and T. Nakamura. 2004. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther. 11:419-430. http://dx.doi.org/10.1038/sj.cgt.7700705.
250. Wendling, O., J.M. Bornert, P. Chambon, and D. Metzger. 2009. Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis. 47:14-18. http://dx.doi.org/10.1002/dvg.20448.
251. Williams, C.S., M. Tsujii, J. Reese, S.K. Dey, and R.N. DuBois. 2000. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105:1589-1594. http://dx.doi.org/10.1172/JCI9621.
252. Wilson, T.R., J. Fridlyand, Y. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y. Wang, J. Sosman, et al. 2012. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487:505-509. http://dx.doi.org/10.1038/nature11249.
253. Witkiewicz, A.K., D. Whitaker-Menezes, A. Dasgupta, N.J. Philp, Z. Lin, R. Gandara, S. Sneddon, U.E. Martinez-Outschoorn, F. Sotgia, and M.P. Lisanti. 2012. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 11:1108-1117. http://dx.doi.org/10.4161/cc.11.6.19530.
254. Xing, F., J. Saidou, and K. Watabe. 2010. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed). 15: 166-179. http://dx.doi.org/10.2741/3613.
255. Xu, Z., A. Vonlaufen, P.A. Phillips, E. Fiala-Beer, X. Zhang, L. Yang, A.V. Biankin, D. Goldstein, R.C. Pirola, J.S. Wilson, and M.V. Apte. 2010. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 177:2585-2596. http://dx.doi.org/10.2353/ajpath.2010.090899.
256. Yang, F., J.A. Tuxhorn, S.J. Ressler, S.J. McAlhany, T.D. Dang, and D.R. Rowley. 2005. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 65:8887-8895. http://dx.doi.org/10.1158/0008-5472.CAN-05-1702.
257. Yang, G., D.G. Rosen, Z. Zhang, R.C. Bast Jr., G.B. Mills, J.A. Colacino, I. Mercado-Uribe, and J. Liu. 2006. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. USA. 103:16472-16477. http://dx.doi.org/10.1073/pnas.0605752103.
258. Yauch, R.L., S.E. Gould, S.J. Scales, T. Tang, H. Tian, C.P. Ahn, D. Marshall, L. Fu, T. Januario, D. Kallop, et al. 2008. A paracrine requirement for hedgehog signalling in cancer. Nature. 455:406-410. http://dx.doi.org/10.1038/nature07275.
259. Yin, C., K.J. Evason, K. Asahina, and D.Y. Stainier. 2013. Hepatic stellate cells in liver development, regeneration, and cancer. J. Clin. Invest. 123:1902-1910. http://dx.doi.org/10.1172/JCI66369.
260. Zeisberg, E.M., S. Potenta, L. Xie, M. Zeisberg, and R. Kalluri. 2007. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 67:10123-10128. http://dx.doi.org/10.1158/0008-5472.CAN-07-3127.
261. Zhang, J., L. Chen, X. Liu, T. Kammertoens, T. Blankenstein, and Z. Qin. 2013a. Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens. Cancer Res. 73:2770-2781. http://dx.doi.org/10.1158/0008-5472 .CAN-12-3022.
262. Zhang, X.H., X. Jin, S. Malladi, Y. Zou, Y.H. Wen, E. Brogi, M. Smid, J.A. Foekens, and J. Massagué. 2013b. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell. 154:1060-1073. http://dx.doi.org/10.1016/j.cell.2013.07.036.
263. Zigrino, P., I. Kuhn, T. Bäuerle, J. Zamek, J.W. Fox, S. Neumann, A. Licht, M. Schorpp-Kistner, P. Angel, and C. Mauch. 2009. Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J. Invest. Dermatol. 129:2686-2693. http://dx.doi.org/10.1038/jid .2009.130.